FDA warns US and Australian eye drop companies for GMP violations, making unapproved claims
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionEnforcementGMPManufacturingOTCOTC monographPharmaceuticalsQuality Assurance and ControlSterile drugsUnited StatesUS Food and Drug Administration (FDA)Warning letters